SRS15569696 SAMN31508589 GSM6692853 B16_CD8_dLN_aCD4_1 10090 Mus musculus bioproject 814224 source_name dLN on day 14 after innoculation of B16 strain C57BL/6 treatment anti-CD4 mAb cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+, CD4- CD8+ and CD44high T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569698 SAMN31508588 GSM6692854 B16_CD8_dLN_aCD4_2 10090 Mus musculus bioproject 814224 source_name dLN on day 14 after innoculation of B16 strain C57BL/6 treatment anti-CD4 mAb cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+, CD4- CD8+ and CD44high T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569699 SAMN31508587 GSM6692855 B16_CD8_dLN_aCD4_3 10090 Mus musculus bioproject 814224 source_name dLN on day 14 after innoculation of B16 strain C57BL/6 treatment anti-CD4 mAb cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+, CD4- CD8+ and CD44high T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569700 SAMN31508586 GSM6692856 B16_CD8_dLN_aCD4_4 10090 Mus musculus bioproject 814224 source_name dLN on day 14 after innoculation of B16 strain C57BL/6 treatment anti-CD4 mAb cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+, CD4- CD8+ and CD44high T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569701 SAMN31508585 GSM6692857 B16_CD8_dLN_aCD4_5 10090 Mus musculus bioproject 814224 source_name dLN on day 14 after innoculation of B16 strain C57BL/6 treatment anti-CD4 mAb cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+, CD4- CD8+ and CD44high T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569702 SAMN31508583 GSM6692859 B16_CD8_dLN_aCD4_7 10090 Mus musculus bioproject 814224 source_name dLN on day 14 after innoculation of B16 strain C57BL/6 treatment anti-CD4 mAb cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+, CD4- CD8+ and CD44high T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569703 SAMN31508584 GSM6692858 B16_CD8_dLN_aCD4_6 10090 Mus musculus bioproject 814224 source_name dLN on day 14 after innoculation of B16 strain C57BL/6 treatment anti-CD4 mAb cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+, CD4- CD8+ and CD44high T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569704 SAMN31508582 GSM6692860 B16_CD8_dLN_aCD4_8 10090 Mus musculus bioproject 814224 source_name dLN on day 14 after innoculation of B16 strain C57BL/6 treatment anti-CD4 mAb cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+, CD4- CD8+ and CD44high T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569705 SAMN31508581 GSM6692861 B16_CD8_dLN_CD4PDL1_1 10090 Mus musculus bioproject 814224 source_name dLN on day 14 after innoculation of B16 strain C57BL/6 treatment combination of anti-CD4 and anti-PD-L1 mAbs cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+, CD4- CD8+ and CD44high T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569706 SAMN31508580 GSM6692862 B16_CD8_dLN_CD4PDL1_2 10090 Mus musculus bioproject 814224 source_name dLN on day 14 after innoculation of B16 strain C57BL/6 treatment combination of anti-CD4 and anti-PD-L1 mAbs cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+, CD4- CD8+ and CD44high T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569707 SAMN31508579 GSM6692863 B16_CD8_dLN_CD4PDL1_3 10090 Mus musculus bioproject 814224 source_name dLN on day 14 after innoculation of B16 strain C57BL/6 treatment combination of anti-CD4 and anti-PD-L1 mAbs cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+, CD4- CD8+ and CD44high T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569708 SAMN31508578 GSM6692864 B16_CD8_dLN_CD4PDL1_4 10090 Mus musculus bioproject 814224 source_name dLN on day 14 after innoculation of B16 strain C57BL/6 treatment combination of anti-CD4 and anti-PD-L1 mAbs cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+, CD4- CD8+ and CD44high T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569709 SAMN31508577 GSM6692865 B16_CD8_dLN_CD4PDL1_5 10090 Mus musculus bioproject 814224 source_name dLN on day 14 after innoculation of B16 strain C57BL/6 treatment combination of anti-CD4 and anti-PD-L1 mAbs cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+, CD4- CD8+ and CD44high T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569710 SAMN31508576 GSM6692866 B16_CD8_dLN_CD4PDL1_6 10090 Mus musculus bioproject 814224 source_name dLN on day 14 after innoculation of B16 strain C57BL/6 treatment combination of anti-CD4 and anti-PD-L1 mAbs cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+, CD4- CD8+ and CD44high T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569711 SAMN31508575 GSM6692867 B16_CD8_dLN_CD4PDL1_7 10090 Mus musculus bioproject 814224 source_name dLN on day 14 after innoculation of B16 strain C57BL/6 treatment combination of anti-CD4 and anti-PD-L1 mAbs cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+, CD4- CD8+ and CD44high T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569712 SAMN31508574 GSM6692868 B16_CD8_dLN_CD4PDL1_8 10090 Mus musculus bioproject 814224 source_name dLN on day 14 after innoculation of B16 strain C57BL/6 treatment combination of anti-CD4 and anti-PD-L1 mAbs cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+, CD4- CD8+ and CD44high T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569713 SAMN31508573 GSM6692869 B16_CD8_dLN_CD4PDL1_9 10090 Mus musculus bioproject 814224 source_name dLN on day 14 after innoculation of B16 strain C57BL/6 treatment combination of anti-CD4 and anti-PD-L1 mAbs cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+, CD4- CD8+ and CD44high T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569714 SAMN31508572 GSM6692870 B16_CD8_dLN_CD4PDL1_10 10090 Mus musculus bioproject 814224 source_name dLN on day 14 after innoculation of B16 strain C57BL/6 treatment combination of anti-CD4 and anti-PD-L1 mAbs cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+, CD4- CD8+ and CD44high T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569715 SAMN31508571 GSM6692871 B16_CD8_dLN_Control_1 10090 Mus musculus bioproject 814224 source_name dLN on day 14 after innoculation of B16 strain C57BL/6 treatment Untreated cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+, CD4- CD8+ and CD44high T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569716 SAMN31508569 GSM6692873 B16_CD8_dLN_Control_3 10090 Mus musculus bioproject 814224 source_name dLN on day 14 after innoculation of B16 strain C57BL/6 treatment Untreated cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+, CD4- CD8+ and CD44high T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569717 SAMN31508568 GSM6692874 B16_CD8_dLN_Control_4 10090 Mus musculus bioproject 814224 source_name dLN on day 14 after innoculation of B16 strain C57BL/6 treatment Untreated cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+, CD4- CD8+ and CD44high T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569718 SAMN31508570 GSM6692872 B16_CD8_dLN_Control_2 10090 Mus musculus bioproject 814224 source_name dLN on day 14 after innoculation of B16 strain C57BL/6 treatment Untreated cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+, CD4- CD8+ and CD44high T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569719 SAMN31508567 GSM6692875 B16_CD8_dLN_Control_5 10090 Mus musculus bioproject 814224 source_name dLN on day 14 after innoculation of B16 strain C57BL/6 treatment Untreated cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+, CD4- CD8+ and CD44high T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569720 SAMN31508566 GSM6692876 B16_CD8_dLN_Control_6 10090 Mus musculus bioproject 814224 source_name dLN on day 14 after innoculation of B16 strain C57BL/6 treatment Untreated cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+, CD4- CD8+ and CD44high T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569721 SAMN31508564 GSM6692878 B16_CD8_dLN_PDL1_2 10090 Mus musculus bioproject 814224 source_name dLN on day 14 after innoculation of B16 strain C57BL/6 treatment anti-PD-L1 mAb cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+, CD4- CD8+ and CD44high T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569722 SAMN31508565 GSM6692877 B16_CD8_dLN_PDL1_1 10090 Mus musculus bioproject 814224 source_name dLN on day 14 after innoculation of B16 strain C57BL/6 treatment anti-PD-L1 mAb cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+, CD4- CD8+ and CD44high T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569723 SAMN31508563 GSM6692879 B16_CD8_dLN_PDL1_3 10090 Mus musculus bioproject 814224 source_name dLN on day 14 after innoculation of B16 strain C57BL/6 treatment anti-PD-L1 mAb cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+, CD4- CD8+ and CD44high T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569724 SAMN31508562 GSM6692880 B16_CD8_dLN_PDL1_4 10090 Mus musculus bioproject 814224 source_name dLN on day 14 after innoculation of B16 strain C57BL/6 treatment anti-PD-L1 mAb cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+, CD4- CD8+ and CD44high T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569725 SAMN31508561 GSM6692881 B16_CD8_dLN_PDL1_5 10090 Mus musculus bioproject 814224 source_name dLN on day 14 after innoculation of B16 strain C57BL/6 treatment anti-PD-L1 mAb cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+, CD4- CD8+ and CD44high T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569726 SAMN31508560 GSM6692882 B16_CD8_dLN_PDL1_6 10090 Mus musculus bioproject 814224 source_name dLN on day 14 after innoculation of B16 strain C57BL/6 treatment anti-PD-L1 mAb cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+, CD4- CD8+ and CD44high T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569727 SAMN31508559 GSM6692883 B16_CD8_dLN_PDL1_7 10090 Mus musculus bioproject 814224 source_name dLN on day 14 after innoculation of B16 strain C57BL/6 treatment anti-PD-L1 mAb cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+, CD4- CD8+ and CD44high T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569728 SAMN31508557 GSM6692885 B16_CD8_Tumor_aCD4_2 10090 Mus musculus bioproject 814224 source_name tumor on day 14 after innoculation of B16 strain C57BL/6 treatment anti-CD4 mAb cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+ and CD4- CD8+ T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569729 SAMN31508558 GSM6692884 B16_CD8_Tumor_aCD4_1 10090 Mus musculus bioproject 814224 source_name tumor on day 14 after innoculation of B16 strain C57BL/6 treatment anti-CD4 mAb cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+ and CD4- CD8+ T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569730 SAMN31508556 GSM6692886 B16_CD8_Tumor_aCD4_3 10090 Mus musculus bioproject 814224 source_name tumor on day 14 after innoculation of B16 strain C57BL/6 treatment anti-CD4 mAb cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+ and CD4- CD8+ T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569731 SAMN31508554 GSM6692888 B16_CD8_Tumor_aCD4_5 10090 Mus musculus bioproject 814224 source_name tumor on day 14 after innoculation of B16 strain C57BL/6 treatment anti-CD4 mAb cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+ and CD4- CD8+ T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569732 SAMN31508555 GSM6692887 B16_CD8_Tumor_aCD4_4 10090 Mus musculus bioproject 814224 source_name tumor on day 14 after innoculation of B16 strain C57BL/6 treatment anti-CD4 mAb cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+ and CD4- CD8+ T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569733 SAMN31508553 GSM6692889 B16_CD8_Tumor_aCD4_6 10090 Mus musculus bioproject 814224 source_name tumor on day 14 after innoculation of B16 strain C57BL/6 treatment anti-CD4 mAb cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+ and CD4- CD8+ T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569734 SAMN31508552 GSM6692890 B16_CD8_Tumor_aCD4_7 10090 Mus musculus bioproject 814224 source_name tumor on day 14 after innoculation of B16 strain C57BL/6 treatment anti-CD4 mAb cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+ and CD4- CD8+ T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569735 SAMN31508551 GSM6692891 B16_CD8_Tumor_aCD4_8 10090 Mus musculus bioproject 814224 source_name tumor on day 14 after innoculation of B16 strain C57BL/6 treatment anti-CD4 mAb cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+ and CD4- CD8+ T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569736 SAMN31508550 GSM6692892 B16_CD8_Tumor_CD4PDL1_1 10090 Mus musculus bioproject 814224 source_name tumor on day 14 after innoculation of B16 strain C57BL/6 treatment combination of anti-CD4 and anti-PD-L1 mAbs cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+ and CD4- CD8+ T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569737 SAMN31508549 GSM6692893 B16_CD8_Tumor_CD4PDL1_2 10090 Mus musculus bioproject 814224 source_name tumor on day 14 after innoculation of B16 strain C57BL/6 treatment combination of anti-CD4 and anti-PD-L1 mAbs cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+ and CD4- CD8+ T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569738 SAMN31508548 GSM6692894 B16_CD8_Tumor_CD4PDL1_3 10090 Mus musculus bioproject 814224 source_name tumor on day 14 after innoculation of B16 strain C57BL/6 treatment combination of anti-CD4 and anti-PD-L1 mAbs cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+ and CD4- CD8+ T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569739 SAMN31508547 GSM6692895 B16_CD8_Tumor_CD4PDL1_4 10090 Mus musculus bioproject 814224 source_name tumor on day 14 after innoculation of B16 strain C57BL/6 treatment combination of anti-CD4 and anti-PD-L1 mAbs cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+ and CD4- CD8+ T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569740 SAMN31508546 GSM6692896 B16_CD8_Tumor_CD4PDL1_5 10090 Mus musculus bioproject 814224 source_name tumor on day 14 after innoculation of B16 strain C57BL/6 treatment combination of anti-CD4 and anti-PD-L1 mAbs cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+ and CD4- CD8+ T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569741 SAMN31508545 GSM6692897 B16_CD8_Tumor_CD4PDL1_6 10090 Mus musculus bioproject 814224 source_name tumor on day 14 after innoculation of B16 strain C57BL/6 treatment combination of anti-CD4 and anti-PD-L1 mAbs cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+ and CD4- CD8+ T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569742 SAMN31508544 GSM6692898 B16_CD8_Tumor_CD4PDL1_7 10090 Mus musculus bioproject 814224 source_name tumor on day 14 after innoculation of B16 strain C57BL/6 treatment combination of anti-CD4 and anti-PD-L1 mAbs cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+ and CD4- CD8+ T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569743 SAMN31508543 GSM6692899 B16_CD8_Tumor_CD4PDL1_8 10090 Mus musculus bioproject 814224 source_name tumor on day 14 after innoculation of B16 strain C57BL/6 treatment combination of anti-CD4 and anti-PD-L1 mAbs cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+ and CD4- CD8+ T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569744 SAMN31508542 GSM6692900 B16_CD8_Tumor_CD4PDL1_9 10090 Mus musculus bioproject 814224 source_name tumor on day 14 after innoculation of B16 strain C57BL/6 treatment combination of anti-CD4 and anti-PD-L1 mAbs cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+ and CD4- CD8+ T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569745 SAMN31508541 GSM6692901 B16_CD8_Tumor_CD4PDL1_10 10090 Mus musculus bioproject 814224 source_name tumor on day 14 after innoculation of B16 strain C57BL/6 treatment combination of anti-CD4 and anti-PD-L1 mAbs cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+ and CD4- CD8+ T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569746 SAMN31508540 GSM6692902 B16_CD8_Tumor_Control_1 10090 Mus musculus bioproject 814224 source_name tumor on day 14 after innoculation of B16 strain C57BL/6 treatment Untreated cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+ and CD4- CD8+ T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569747 SAMN31508539 GSM6692903 B16_CD8_Tumor_Control_2 10090 Mus musculus bioproject 814224 source_name tumor on day 14 after innoculation of B16 strain C57BL/6 treatment Untreated cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+ and CD4- CD8+ T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569748 SAMN31508538 GSM6692904 B16_CD8_Tumor_Control_3 10090 Mus musculus bioproject 814224 source_name tumor on day 14 after innoculation of B16 strain C57BL/6 treatment Untreated cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+ and CD4- CD8+ T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569749 SAMN31508537 GSM6692905 B16_CD8_Tumor_Control_4 10090 Mus musculus bioproject 814224 source_name tumor on day 14 after innoculation of B16 strain C57BL/6 treatment Untreated cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+ and CD4- CD8+ T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569750 SAMN31508536 GSM6692906 B16_CD8_Tumor_Control_5 10090 Mus musculus bioproject 814224 source_name tumor on day 14 after innoculation of B16 strain C57BL/6 treatment Untreated cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+ and CD4- CD8+ T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569751 SAMN31508535 GSM6692907 B16_CD8_Tumor_Control_6 10090 Mus musculus bioproject 814224 source_name tumor on day 14 after innoculation of B16 strain C57BL/6 treatment Untreated cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+ and CD4- CD8+ T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569752 SAMN31508534 GSM6692908 B16_CD8_Tumor_PDL1_1 10090 Mus musculus bioproject 814224 source_name tumor on day 14 after innoculation of B16 strain C57BL/6 treatment anti-PD-L1 mAb cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+ and CD4- CD8+ T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569753 SAMN31508533 GSM6692909 B16_CD8_Tumor_PDL1_2 10090 Mus musculus bioproject 814224 source_name tumor on day 14 after innoculation of B16 strain C57BL/6 treatment anti-PD-L1 mAb cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+ and CD4- CD8+ T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569754 SAMN31508532 GSM6692910 B16_CD8_Tumor_PDL1_3 10090 Mus musculus bioproject 814224 source_name tumor on day 14 after innoculation of B16 strain C57BL/6 treatment anti-PD-L1 mAb cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+ and CD4- CD8+ T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569755 SAMN31508531 GSM6692911 B16_CD8_Tumor_PDL1_4 10090 Mus musculus bioproject 814224 source_name tumor on day 14 after innoculation of B16 strain C57BL/6 treatment anti-PD-L1 mAb cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+ and CD4- CD8+ T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569756 SAMN31508530 GSM6692912 B16_CD8_Tumor_PDL1_5 10090 Mus musculus bioproject 814224 source_name tumor on day 14 after innoculation of B16 strain C57BL/6 treatment anti-PD-L1 mAb cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+ and CD4- CD8+ T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569757 SAMN31508529 GSM6692913 B16_CD8_Tumor_PDL1_6 10090 Mus musculus bioproject 814224 source_name tumor on day 14 after innoculation of B16 strain C57BL/6 treatment anti-PD-L1 mAb cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+ and CD4- CD8+ T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569758 SAMN31508528 GSM6692914 B16_CD8_Tumor_PDL1_7 10090 Mus musculus bioproject 814224 source_name tumor on day 14 after innoculation of B16 strain C57BL/6 treatment anti-PD-L1 mAb cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+ and CD4- CD8+ T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569759 SAMN31508527 GSM6692915 LLC_CD8_dLN_aCD4_1 10090 Mus musculus bioproject 814224 source_name dLN on day 14 after innoculation of LLC strain C57BL/6 treatment anti-CD4 mAb cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+, CD4- CD8+ and CD44high T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569760 SAMN31508526 GSM6692916 LLC_CD8_dLN_aCD4_2 10090 Mus musculus bioproject 814224 source_name dLN on day 14 after innoculation of LLC strain C57BL/6 treatment anti-CD4 mAb cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+, CD4- CD8+ and CD44high T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569761 SAMN31508525 GSM6692917 LLC_CD8_dLN_aCD4_3 10090 Mus musculus bioproject 814224 source_name dLN on day 14 after innoculation of LLC strain C57BL/6 treatment anti-CD4 mAb cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+, CD4- CD8+ and CD44high T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569762 SAMN31508524 GSM6692918 LLC_CD8_dLN_aCD4_4 10090 Mus musculus bioproject 814224 source_name dLN on day 14 after innoculation of LLC strain C57BL/6 treatment anti-CD4 mAb cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+, CD4- CD8+ and CD44high T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569763 SAMN31508522 GSM6692920 LLC_CD8_dLN_aCD4_6 10090 Mus musculus bioproject 814224 source_name dLN on day 14 after innoculation of LLC strain C57BL/6 treatment anti-CD4 mAb cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+, CD4- CD8+ and CD44high T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569764 SAMN31508523 GSM6692919 LLC_CD8_dLN_aCD4_5 10090 Mus musculus bioproject 814224 source_name dLN on day 14 after innoculation of LLC strain C57BL/6 treatment anti-CD4 mAb cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+, CD4- CD8+ and CD44high T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569765 SAMN31508521 GSM6692921 LLC_CD8_dLN_CD4PDL1_1 10090 Mus musculus bioproject 814224 source_name dLN on day 14 after innoculation of LLC strain C57BL/6 treatment combination of anti-CD4 and anti-PD-L1 mAbs cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+, CD4- CD8+ and CD44high T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569766 SAMN31508519 GSM6692923 LLC_CD8_dLN_CD4PDL1_3 10090 Mus musculus bioproject 814224 source_name dLN on day 14 after innoculation of LLC strain C57BL/6 treatment combination of anti-CD4 and anti-PD-L1 mAbs cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+, CD4- CD8+ and CD44high T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569767 SAMN31508520 GSM6692922 LLC_CD8_dLN_CD4PDL1_2 10090 Mus musculus bioproject 814224 source_name dLN on day 14 after innoculation of LLC strain C57BL/6 treatment combination of anti-CD4 and anti-PD-L1 mAbs cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+, CD4- CD8+ and CD44high T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569768 SAMN31508518 GSM6692924 LLC_CD8_dLN_Control_1 10090 Mus musculus bioproject 814224 source_name dLN on day 14 after innoculation of LLC strain C57BL/6 treatment Untreated cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+, CD4- CD8+ and CD44high T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569769 SAMN31508517 GSM6692925 LLC_CD8_dLN_Control_2 10090 Mus musculus bioproject 814224 source_name dLN on day 14 after innoculation of LLC strain C57BL/6 treatment Untreated cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+, CD4- CD8+ and CD44high T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569770 SAMN31508516 GSM6692926 LLC_CD8_dLN_Control_3 10090 Mus musculus bioproject 814224 source_name dLN on day 14 after innoculation of LLC strain C57BL/6 treatment Untreated cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+, CD4- CD8+ and CD44high T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569771 SAMN31508515 GSM6692927 LLC_CD8_dLN_Control_4 10090 Mus musculus bioproject 814224 source_name dLN on day 14 after innoculation of LLC strain C57BL/6 treatment Untreated cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+, CD4- CD8+ and CD44high T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569772 SAMN31508514 GSM6692928 LLC_CD8_dLN_Control_5 10090 Mus musculus bioproject 814224 source_name dLN on day 14 after innoculation of LLC strain C57BL/6 treatment Untreated cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+, CD4- CD8+ and CD44high T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569773 SAMN31508513 GSM6692929 LLC_CD8_dLN_Control_6 10090 Mus musculus bioproject 814224 source_name dLN on day 14 after innoculation of LLC strain C57BL/6 treatment Untreated cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+, CD4- CD8+ and CD44high T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569774 SAMN31508511 GSM6692931 LLC_CD8_dLN_PDL1_2 10090 Mus musculus bioproject 814224 source_name dLN on day 14 after innoculation of LLC strain C57BL/6 treatment anti-PD-L1 mAb cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+, CD4- CD8+ and CD44high T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569775 SAMN31508512 GSM6692930 LLC_CD8_dLN_PDL1_1 10090 Mus musculus bioproject 814224 source_name dLN on day 14 after innoculation of LLC strain C57BL/6 treatment anti-PD-L1 mAb cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+, CD4- CD8+ and CD44high T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569776 SAMN31508510 GSM6692932 LLC_CD8_dLN_PDL1_3 10090 Mus musculus bioproject 814224 source_name dLN on day 14 after innoculation of LLC strain C57BL/6 treatment anti-PD-L1 mAb cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+, CD4- CD8+ and CD44high T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569777 SAMN31508509 GSM6692933 LLC_CD8_dLN_PDL1_4 10090 Mus musculus bioproject 814224 source_name dLN on day 14 after innoculation of LLC strain C57BL/6 treatment anti-PD-L1 mAb cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+, CD4- CD8+ and CD44high T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569778 SAMN31508508 GSM6692934 LLC_CD8_dLN_PDL1_5 10090 Mus musculus bioproject 814224 source_name dLN on day 14 after innoculation of LLC strain C57BL/6 treatment anti-PD-L1 mAb cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+, CD4- CD8+ and CD44high T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569779 SAMN31508507 GSM6692935 LLC_CD8_Tumor_aCD4_1 10090 Mus musculus bioproject 814224 source_name tumor on day 14 after innoculation of LLC strain C57BL/6 treatment anti-CD4 mAb cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+ and CD4- CD8+ T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569780 SAMN31508506 GSM6692936 LLC_CD8_Tumor_aCD4_2 10090 Mus musculus bioproject 814224 source_name tumor on day 14 after innoculation of LLC strain C57BL/6 treatment anti-CD4 mAb cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+ and CD4- CD8+ T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569781 SAMN31508505 GSM6692937 LLC_CD8_Tumor_aCD4_3 10090 Mus musculus bioproject 814224 source_name tumor on day 14 after innoculation of LLC strain C57BL/6 treatment anti-CD4 mAb cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+ and CD4- CD8+ T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569782 SAMN31508503 GSM6692939 LLC_CD8_Tumor_aCD4_5 10090 Mus musculus bioproject 814224 source_name tumor on day 14 after innoculation of LLC strain C57BL/6 treatment anti-CD4 mAb cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+ and CD4- CD8+ T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569783 SAMN31508504 GSM6692938 LLC_CD8_Tumor_aCD4_4 10090 Mus musculus bioproject 814224 source_name tumor on day 14 after innoculation of LLC strain C57BL/6 treatment anti-CD4 mAb cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+ and CD4- CD8+ T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569784 SAMN31508502 GSM6692940 LLC_CD8_Tumor_aCD4_6 10090 Mus musculus bioproject 814224 source_name tumor on day 14 after innoculation of LLC strain C57BL/6 treatment anti-CD4 mAb cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+ and CD4- CD8+ T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569785 SAMN31508501 GSM6692941 LLC_CD8_Tumor_CD4PDL1_1 10090 Mus musculus bioproject 814224 source_name tumor on day 14 after innoculation of LLC strain C57BL/6 treatment combination of anti-CD4 and anti-PD-L1 mAbs cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+ and CD4- CD8+ T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569786 SAMN31508500 GSM6692942 LLC_CD8_Tumor_CD4PDL1_2 10090 Mus musculus bioproject 814224 source_name tumor on day 14 after innoculation of LLC strain C57BL/6 treatment combination of anti-CD4 and anti-PD-L1 mAbs cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+ and CD4- CD8+ T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569787 SAMN31508499 GSM6692943 LLC_CD8_Tumor_CD4PDL1_3 10090 Mus musculus bioproject 814224 source_name tumor on day 14 after innoculation of LLC strain C57BL/6 treatment combination of anti-CD4 and anti-PD-L1 mAbs cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+ and CD4- CD8+ T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569788 SAMN31508498 GSM6692944 LLC_CD8_Tumor_Control_1 10090 Mus musculus bioproject 814224 source_name tumor on day 14 after innoculation of LLC strain C57BL/6 treatment Untreated cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+ and CD4- CD8+ T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569789 SAMN31508497 GSM6692945 LLC_CD8_Tumor_Control_2 10090 Mus musculus bioproject 814224 source_name tumor on day 14 after innoculation of LLC strain C57BL/6 treatment Untreated cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+ and CD4- CD8+ T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569790 SAMN31508495 GSM6692947 LLC_CD8_Tumor_Control_4 10090 Mus musculus bioproject 814224 source_name tumor on day 14 after innoculation of LLC strain C57BL/6 treatment Untreated cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+ and CD4- CD8+ T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569791 SAMN31508496 GSM6692946 LLC_CD8_Tumor_Control_3 10090 Mus musculus bioproject 814224 source_name tumor on day 14 after innoculation of LLC strain C57BL/6 treatment Untreated cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+ and CD4- CD8+ T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569792 SAMN31508494 GSM6692948 LLC_CD8_Tumor_Control_5 10090 Mus musculus bioproject 814224 source_name tumor on day 14 after innoculation of LLC strain C57BL/6 treatment Untreated cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+ and CD4- CD8+ T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569793 SAMN31508493 GSM6692949 LLC_CD8_Tumor_Control_6 10090 Mus musculus bioproject 814224 source_name tumor on day 14 after innoculation of LLC strain C57BL/6 treatment Untreated cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+ and CD4- CD8+ T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569794 SAMN31508492 GSM6692950 LLC_CD8_Tumor_PDL1_1 10090 Mus musculus bioproject 814224 source_name tumor on day 14 after innoculation of LLC strain C57BL/6 treatment anti-PD-L1 mAb cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+ and CD4- CD8+ T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569795 SAMN31508491 GSM6692951 LLC_CD8_Tumor_PDL1_2 10090 Mus musculus bioproject 814224 source_name tumor on day 14 after innoculation of LLC strain C57BL/6 treatment anti-PD-L1 mAb cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+ and CD4- CD8+ T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569796 SAMN31508490 GSM6692952 LLC_CD8_Tumor_PDL1_3 10090 Mus musculus bioproject 814224 source_name tumor on day 14 after innoculation of LLC strain C57BL/6 treatment anti-PD-L1 mAb cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+ and CD4- CD8+ T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569797 SAMN31508488 GSM6692954 LLC_CD8_Tumor_PDL1_5 10090 Mus musculus bioproject 814224 source_name tumor on day 14 after innoculation of LLC strain C57BL/6 treatment anti-PD-L1 mAb cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+ and CD4- CD8+ T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569798 SAMN31508489 GSM6692953 LLC_CD8_Tumor_PDL1_4 10090 Mus musculus bioproject 814224 source_name tumor on day 14 after innoculation of LLC strain C57BL/6 treatment anti-PD-L1 mAb cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+ and CD4- CD8+ T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569799 SAMN31508487 GSM6692955 B16_CD8_Tumor_CD4PDL1_sup1 10090 Mus musculus bioproject 814224 source_name tumor on day 14 after innoculation of LLC strain C57BL/6 treatment combination of anti-CD4 and anti-PD-L1 mAbs cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+ and CD4- CD8+ T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569800 SAMN31508486 GSM6692956 B16_CD8_Tumor_DP_CD4PDL1_sup1 10090 Mus musculus bioproject 814224 source_name tumor on day 14 after innoculation of LLC strain C57BL/6 treatment combination of anti-CD4 and anti-PD-L1 mAbs cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+ and CD4- CD8+ T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569801 SAMN31508485 GSM6692957 B16_CD8_Tumor_Ly108_CD4PDL1_sup1 10090 Mus musculus bioproject 814224 source_name tumor on day 14 after innoculation of LLC strain C57BL/6 treatment combination of anti-CD4 and anti-PD-L1 mAbs cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+ and CD4- CD8+ T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569802 SAMN31508484 GSM6692958 B16_CD8_Tumor_PD1nega_CD4PDL1_sup1 10090 Mus musculus bioproject 814224 source_name tumor on day 14 after innoculation of LLC strain C57BL/6 treatment combination of anti-CD4 and anti-PD-L1 mAbs cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+ and CD4- CD8+ T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing SRS15569803 SAMN31508483 GSM6692959 B16_CD8_Tumor_Tim3_CD4PDL1_sup1 10090 Mus musculus bioproject 814224 source_name tumor on day 14 after innoculation of LLC strain C57BL/6 treatment combination of anti-CD4 and anti-PD-L1 mAbs cell type Intravenous (i.v.) staining-negative, lineage-negative (CD11b, B220, NK1.1 and Ter119), TCRbeta+ and CD4- CD8+ T cells age 8 weeks Sex female tumour cell line B16F10 melanoma organ B16F10 date 0 geo_loc_name missing collection_date missing